论文部分内容阅读
目的建立HPLC法测定联用利福平前后HIV感染者血浆中的EFV浓度,为个体化治疗提供依据。方法色谱柱为Agilent Eclipse XDB-C_(18)(4.6 mm×150 mm,5μm),流动相为乙腈∶水(58∶42),流速为0.8 m L/min,检测波长为244 nm,柱温30℃,进样量20μL,测定3例HIV感染者。结果 EFV保留时间为7.8 min,标准曲线方程为y=3.409 5x-0.004 8(r~2=0.999 4),线性范围为0.04~20μg/m L。3例患者使用利福平后EFV浓度均有所下降,平均降幅为0.567μg/m L。结论该方法灵敏、准确可行,可用于测定人血浆中EFV浓度,联用利福平可降低EFV浓度。
OBJECTIVE To establish an HPLC method for the determination of EFV in the plasma of HIV-infected patients before and after the combination of rifampin and provide a basis for individualized treatment. Methods The column was Agilent Eclipse XDB-C 18 (4.6 mm × 150 mm, 5 μm). The mobile phase was acetonitrile: water (58:42), the flow rate was 0.8 m L / min and the detection wavelength was 244 nm. 30 ℃, injection volume 20μL, determination of 3 cases of HIV-infected persons. Results The retention time of EFV was 7.8 min. The standard curve equation was y = 3.409 5x-0.004 8 (r ~ 2 = 0.999 4) with a linear range of 0.04 ~ 20 μg / m L. The EFV concentrations of 3 patients decreased with rifampin, with an average decrease of 0.567 μg / m L. Conclusion The method is sensitive, accurate and feasible. It can be used to determine the concentration of EFV in human plasma. Combined with rifampicin can reduce the concentration of EFV.